Vaxcyte (PCVX) Free Cash Flow (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Free Cash Flow of -$282.7 million for Q1 2026, down 64.67% year-over-year from -$800.2 million in Q1 2025, and down 24.66% quarter-over-quarter from -$226.8 million in Q4 2025.
Powered by 
Analysis
Vaxcyte (PCVX) Free Cash Flow (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Free Cash Flow for 8 consecutive years, with -$282.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 64.67% year-over-year to -$282.7 million; the TTM figure through Mar 2026 stood at -$774.1 million (down 60.63% YoY), while the FY2025 annual figure was -$663.1 million, down 39.59% from the prior year.
- Free Cash Flow fell to -$282.7 million in Q1 2026 per PCVX's latest filing, from -$226.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$28.4 million in Q1 2022 and bottomed at -$282.7 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$112.0 million across 5 years, with a median of -$115.4 million in 2024.
- On a YoY basis, Free Cash Flow climbed as much as 20.09% in 2024 and fell as far as 209.2% in 2024.
- Vaxcyte's Free Cash Flow stood at -$60.6 million in 2022, then tumbled by 138.23% to -$144.4 million in 2023, then increased by 20.09% to -$115.4 million in 2024, then sank by 96.5% to -$226.8 million in 2025, then decreased by 24.66% to -$282.7 million in 2026.
- Business Quant data shows PCVX's Free Cash Flow at -$282.7 million in Q1 2026, -$226.8 million in Q4 2025, and -$141.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - | -232.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -232.55 Mn |
| Mar 31, 2026 | -286.97 Mn |
| Dec 31, 2025 | -227.49 Mn |
| Sep 30, 2025 | -147.13 Mn |
| Jun 30, 2025 | -122.98 Mn |
| Mar 31, 2025 | -171.70 Mn |
| Dec 31, 2024 | -115.42 Mn |
| Sep 30, 2024 | -65.66 Mn |
| Jun 30, 2024 | -121.13 Mn |
| Mar 31, 2024 | -172.84 Mn |
| Dec 31, 2023 | -134.06 Mn |
| Sep 30, 2023 | -64.19 Mn |
| Jun 30, 2023 | -61.30 Mn |
| Mar 31, 2023 | -53.30 Mn |
| Dec 31, 2022 | -66.36 Mn |
| Sep 30, 2022 | -39.39 Mn |
| Jun 30, 2022 | -40.06 Mn |
| Mar 31, 2022 | -30.62 Mn |
| Dec 31, 2021 | -52.48 Mn |
| Sep 30, 2021 | -30.13 Mn |